Somatostatinoma

Anatomic location and clinical features: 1) Pancreatic somatostatinomas - 50-60% of cases, typically in pancreatic head or body, present with full inhibitory triad; tend to be larger (mean 5 cm) with higher metastatic potential; 2) Duodenal somatostatinomas - 40-50% of cases, often in periampullary region, presenting with biliary or pancreatic duct obstruction (jaundice, pain), GI bleeding, weight loss; commonly contain psammoma bodies on histology; less likely to cause the full functional syndrome; 3) Inhibitory triad pathophysiology - somatostatin inhibits insulin and glucagon secretion (diabetes typically mild and non-ketotic), inhibits cholecystokinin and gallbladder contractility (cholelithiasis common), inhibits pancreatic exocrine secretion (steatorrhea), inhibits gastric acid (hypochlorhydria), inhibits intestinal motility; 4) Other manifestations - weight loss, abdominal pain, diarrhea, jaundice (in periampullary tumors), upper GI bleeding; 5) Genetic associations - duodenal somatostatinomas in 30-50% of NF1 (von Recklinghausen disease) - usually periampullary, often with pheochromocytoma and gastric carcinoid; MEN1 (rare); von Hippel-Lindau (rare); tuberous sclerosis (rare).

Diagnosis and localization: 1) Plasma somatostatin - elevated levels (>30 pg/mL highly suggestive, normal <100; many pancreatic primary >1000 pg/mL); chromogranin A elevated in 70-100%; pancreatic polypeptide may be co-elevated; insulin and glucagon (low or normal); 2) Imaging - contrast-enhanced CT abdomen/pelvis to identify primary, regional and hepatic metastases; MRI with hepatobiliary phase highly sensitive for liver metastases; endoscopic ultrasound for ampullary and duodenal localization, with FNA biopsy; ERCP for periampullary lesions; 3) Functional imaging - 68Ga-DOTATATE PET/CT highly sensitive for staging and demonstrating somatostatin receptor expression; FDG-PET reserved for high-grade tumors; 4) Histopathology - well-differentiated NET, chromogranin A and synaptophysin positive, somatostatin staining confirms cell type; psammoma bodies characteristic in duodenal lesions; Ki-67 grades the tumor; 5) Workup for genetic syndromes - clinical evaluation for NF1 (cafe-au-lait spots, neurofibromas, axillary freckling, Lisch nodules); plasma metanephrines or urinary fractionated metanephrines for pheochromocytoma in NF1; 6) Differential diagnosis - secondary somatostatin elevation in renal failure, severe stress, ectopic production; need histologic confirmation.

Treatment and prognosis: 1) Surgery - distal pancreatectomy or Whipple procedure for pancreatic primary; pancreatoduodenectomy (Whipple) for periampullary and head tumors; local resection or transduodenal excision rarely sufficient (high recurrence); regional lymphadenectomy for staging; cholecystectomy concurrent (high cholelithiasis risk); 2) Liver-directed therapy - resection if isolated metastases, transarterial embolization (TAE)/chemoembolization (TACE), radiofrequency ablation, peptide receptor radionuclide therapy (177Lu-DOTATATE) for receptor-positive metastatic disease; 3) Medical therapy - somatostatin analogs (octreotide LAR, lanreotide) for symptom control and tumor stabilization, though theoretical concern of further inhibition; in practice, well tolerated; everolimus and sunitinib for progressive metastatic disease; 4) Chemotherapy - capecitabine + temozolomide, streptozocin-based for high-grade or rapidly progressive tumors; 5) Supportive care - insulin or oral hypoglycemics for diabetes (often resolves after resection), pancreatic enzyme replacement therapy (PERT) for steatorrhea, cholecystectomy for symptomatic cholelithiasis, biliary stenting for obstructive jaundice; 6) NF1-associated cases - require thorough screening for pheochromocytoma before surgery, lifelong surveillance for second primaries; 7) Prognosis - 5-year survival 75-85% if resected, 30-50% if metastatic; size, grade, and metastases are key prognostic factors; multidisciplinary NET center management essential; lifelong surveillance for recurrence.